Skip to main content Accessibility help

Animal Models of Alzheimer's Disease: Behavior, Pharmacology, Transplants

  • V. Haroutunian (a1), P.D. Kanof (a1), G.K. Tsuboyama (a1), G.A. Campbell (a1) and K.L. Davis (a1)...


Physostigmine, oxotremorine, RS-86, and a combination of piracetam and lecithin, have all been studied in patients with Alzheimer's disease. Intravenous physostigmine produced a significant improvement in patients' ability to recognize words and particularly to distinguish words they had never seen before from words previously presented. A subgroup of Alzheimer's patients had a clinically meaningful improvement to treatment with oral physostigmine, with the degree of improvement correlating with the ability of oral physostigmine to increase the nocturnal secretion of Cortisol. No statistically significant differences of piracetam or piracetam and lecithin, compared to placebo were noted, however, the ratio of red cell to plasma choline might be associated with treatment responsivity. The potential therapeutic efficacy of oxotremorine proved all but impossible to assess due to concomitant adverse effects, particularly dysphoria. Results with another cholinergic agonist, RS-86, will be reported. This drug appeared to be better tolerated than oxotremorine.

Animals with a kianic acid induced cortical depletion of choline acetyltransferase were found to have a significant impairment in retention of a passive avoidance task, an abnormality that was readily reversible by physostigmine, oxotremorine and 4-amino-pyridine. Cysteamine, a depletor of somatostatin, also produced a comparable deficit.

    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Animal Models of Alzheimer's Disease: Behavior, Pharmacology, Transplants
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Animal Models of Alzheimer's Disease: Behavior, Pharmacology, Transplants
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Animal Models of Alzheimer's Disease: Behavior, Pharmacology, Transplants
      Available formats


Corresponding author

Psychiatry Service, Bronx VA Medical Center, 130 W. Kingsbridge Road, Bronx, N.Y., U.S.A. 10468


Hide All
1.Whitehouse, PJ, Price, DL, Struble, RG, Clark, AW, Coyle, JT.Alzheimer’s disease and senile demenlia: loss of neurons in the basal forebrain. Science 1982; 215: 12371239.
2.Candy, JM, Perry, RH, Perry, EK, Irving, D, Blessed, G, Fairbairn, , Tomlinson, RL.Pathological changes in the nucleus of Meynert in Alzheimer’s disease and Parkinson’s disease. J Neurol Science 1983; 54: 277289.
3.Pearson, RCA, Sofroniew, MV, Cuello, AC.Powell, TPS, Eckenstein, F, Esiri, MM, Wilcock, GK.Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of Alzheimer’s type demonstrated by immunohistochemical staining for choline acetyl-transferase. Brain Research 1983; 289: 370374.
4.McKinney, M, Coyle, JT, Hedeen, JC.Topographic analysis of the innervation of the rat neocortex and hippocampus by basal forebrain cholinergic system. J Comparative Neurology 1983; 217: 103121.
5.Johnston, MV, McKinney, M, Coyle, JT.Neocortical cholinergic innervation: A description of extrinsic and intrinsic components in the rat. Experimental Brain Research 1981; 43: 159172.
6.Wenk, H, Volker, B, Meyer, U.Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical area in rats. Brain Research Reviews 1980; 2: 295316.
7.Fibiger, HC.The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Research Reviews 1982; 4: 327388.
8.Davies, P, Maloney, AJF.Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976; 2: 1403.
9.Perry, EK, Perry, RH, Blessed, G, Tomlinson, BE.Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1976; 2: 143.
10.Perry, EK, Tomlinson, BE, Blessed, G, Bergmann, K, Gibson, PH, Perry, RH.Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal 1978; 2: 14571459.
11.Bartus, RT, Dean, RL, Beer, B, Lippa, AS.The cholinergic hypothesis of geriatric memory dysfunction: A critical review. Science 1982;217:408417.
12.LoConte, G, Bartolini, L, Castamenti, F, Marconcini-Pepeu, I, Pepeu, G.Lesions of cholinergic forebrain nuclei: Changes in avoidance behavior and scopolamine action. Pharmacology Biochemistry and Behavior 1982; 17: 933937.
13.Flicker, C, Dean, RL, Watkins, DL, Fisher, SK, Bartus, RT.Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacology Biochemistry and Behavior 1983; 18: 973981.
14.Altman, HJ, Crosland, RD, Jenden, DJ, Berman, RF.Further characterizations of the nature of the behavioral and neurochemical effects of lesions to the nucleus basalis of Meynert in the rat. Neurobiology of Aging 1985; 6: 125130.
15.Haroutunian, V, Kanof, P, Davis, KL.Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sciences 1985; 945952.
17.Bartus, RT, Pontecorvo, M, Flicker, C, Dean, RL, Figueiredo, JC.Behavioral recovery following bilateral lesions of the nucleus basalis does not occur spontaneously. Pharmacology, Biochemistry and Behavior 1986; 24: 12871292.
18.Wenk, GL, Olton, DS.Recovery of neocortical choline acetyltransferase activity following ibotenic acid injection into the nucleus basalis of Meynert in rats. Brain Research 1984; 293: 184186.
19.Bartus, RT, Flicker, C, Dean, RL, Pontecorvo, M, Figueiredo, JC, Fisher, SK.Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholin-ergicdeficiencies. Pharmacology, Biochemistry and Behavior 1985; 23: 125135.
20.Salamone, JD, Beart, PM, Alpert, JE, Iversen, SD.Impairment in T-maze alternation following nucleus basalis magnocellularis lesions in rats. Behavioral Brain Research 1984; 13: 6370.
21.Murray, CL, Fibiger, HC.Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by Physostigmine. Neuroscience 1985; 19: 10251032.
22.Murray, CL, Fibiger, HC.Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behavioral Neuroscience 1986; 100: 2332.
23.Beal, MF, Mazurek, MF, Tran, VT, Chattha, G, Bird, ED, Martin, JB.Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289291.
24.Davies, P, Katzman, R,Terry, RD.Reducedsomatostatin-likeimmunoreactivity in cerebral cortex from cases of Alzheimer’s disease Alzheimer senile dementia. Nature 1980; 288: 279280.
25.Rossor, MN, Emson, PC, Mountjoy, CQ, Roth, M, Iversen, LL.Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer’s type. Neuroscience Letters 1980; 20: 373377.
26.Bennett-Clarke, C, Romagnano, MA, Joseph, SA.Distribution of somatostatin in the rat brain: telencephalon and diencephalon. Brain Research 1980; 188: 473486.
27.Johansson, O, Hokfelt, T, Elde, RP.Immunohistochemical distribution of somatostatin-like-immunoreactivity in the central nervous system of the rat. Neuroscience 1984; 13: 265339.
28.Haroutunian, V, Mantin, R, Campbell, GA, Tsuboyama, GK, Davis, KL.Cysteamine-induced depletion of central somatostatin-like immunoactivity: Effects on behavior, learning, memory and brain neurochemistry. Brain Research (in press).
29.DiLiberato, EJ, Distefano, V, Smith, JC.Mechanisms and kinetics of the inhibition of dopamine-B-hydroxylase by 2-mercapto-ethylguanidine. Biochemical Pharmacology 1973;22:29612972.
30.Vecsei, L, Kiraly, C, Bollok, I, Nagy, A, Verga, J, Penke, B, Telegdy, G.Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacology, Biochemistry and Behavior 1984; 21: 833837.
31.Bakhit, C, Swerdlow, NR.Behavioral changes following central injection of cysteamine in rats. Soc Neuroscience Abst 1984; 10: 182.
32.Cutler, NR, Haxby, JV, Narang, PK, May, C, Burg, C, Reines, SA.Evaluation of an analogue of somatostatin (L363, 586) in Alzheimer’s disease. New England J Medicine 1985; 312: 725.
33.Adolfsson, R, Gottfries, CG, Roos, BE, Winblat, B.Changes in the brain catecholamines in patients with dementia of Alzheimer’s type. British J Psychiatry; 1979: 135: 216223.
34.Benton, JS, Bowen, DM, Allen, SJ, Haan, EA, Davison, N, Neary, D, Murphy, RP, Snowden, JS.Alzheimer’s disease as a disorder of isodendritic core. Lancet 1982; 20: 456.
35.Perry, EK, Tomlinson, BE, Blessed, G, Perry, RH, Cross, AJ, Crow, TJ.Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease. J Neurol Science 1981;51: 279337.
36.Mason, ST.Noradrenaline in the brain: Progress in theories of behavioral function. Progressin Neurobiology 1981; 16:262303.
37.McNaughton, N, Mason, ST.The neuropsychology and neuropharmacology of the dorsal ascending noradrenergic bundle- A review. Progress in Neurobiology 1980; 14: 157219.
38.Gold, PE, Zometzer, SF.The mnemon and itsjuices: Neuromodulation of memory processes. Behavioral and Neural Biology 1983; 38: 151189.
39.Glavin, GB.Stress and brain noradrenaline: A review. Neuroscience and Biobehavioral Reviews 1985; 9: 233243.
40.Mason, ST.Noradrenaline: Reward or extinction? Neuroscience & Biobehavioral Reviews 1979; 3: 110.
41.Mason, ST, Fibiger, HC.6-OHDA lesions of the dorsal noradrenergic bundle alters extinction of passive avoidance. Brain Research 1978; 152: 209214.
42.Mason, ST, Iversen, SD.Effects of selective forebrain noradrenaline loss on behavioral inhibition in the rat. J Comparative and Physiological Psychology 1977; 91: 165173.
43.Chrobak, JJ, Dehaven, DL, Walsh, TJ.Depletion of brain noradrenaline with DSP-4 does not alter acquisition or performance of a radial-arm maze task. Behavioral and Neural Biology 1985; 44: 144150.
44.Mason, ST, Fibiger, HC.Noradrenaline and spatial memory. Brain Research 1978; 156: 382386.
45.Arnstein, AFT, Goldman-Rakic, PS.Catecholamines and cognitive decline in aged nonhuman primates. Annals of the New York Academy of Sciences 1985; 444: 218234.
46.Goldman-Rakic, PS, Brown, RM.Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981; 6: 177187.
47.Gold, PE, Murphy, JM.Brain noradrenergic responses to training and to amnestic frontal cortex stimulation. Pharmacology, Biochemistry and Behavior 1980, 13: 257263.
48.Gold, PE, McGaugh, JL.Hormones and memory. In: Miller, LH, Sandman, CA, Kastin, AJ, eds. Neuropeptide Influences on the Brain and Behavior 1977; 127143.
49.Welsh, KA, Gold, PE.Brain catecholamines and memory modulation: Effects of footshock, amygdala implantation, and stimulation. Behavioral and Neural Biology 1985; 43: 119131.
50.Gold, PE, Robertson, NL, Delanoy, RL.Post-training brain catecholamine levels: lack of response to water-motivated training. Behavioral and Neurobiology 1985; 44: 425433.
51.Haroutunian, V, Riccio, DC.Effects of arousal conditions duringreinstatement treatments upon learned fear in young rats. Developmental Psychobiology 1977; 10: 2532.
52.Gold, PE, van Buskirk, RB.Facilitation of time-dependent memory processes with post-trialepinephrineinjections. Behavioral Biology 1975; 13: 145153.
53.Levy, A, Brandies, R, Dachir, S, Luz, S, Karton, Y, Heldman, E, Pittel, Z, Fisher, A.Reversal of AF64A-induced memory impairment by cholinergic compounds. Neuroscience Abstracts 1985, 11:2, 875.
54.Haroutunian, V, Barns, E, Davis, KL.Cholinergic modulation of memory in rats. Psychopharmacology 1985; 87: 266271.
55.Flood, JS, Landry, DW, Jarvik, ME.Cholinergic receptor interactions and their effects on long-term memory processing. Brain Research 1981, 215: 177185.
56.Flood, JS, Smith, GE, Cherkin, A.Memory retention: Potentiation of cholinergic drug combinations in mice. Neurobiology of Aging 1983; 4: 3743.
57.Ridley, RM, Murray, TK, Johnson, JA, Baker, HF.Learning Impairment following lesion of the basal nucleus of Meynert in marmoset: Modification by cholinergic drugs. Brain Research 1986; 376: 108116.
58.Mohs, RC, Davis, BM, Johns, CA, Mathe, AA, Greenwald, BS, Horvath, TB, Davis, KL.Oral physostigmine treatment of patients with AD. Amer J Psychiatry 1985; 142: 2833.
59.Haroutunian, V, Davis, KL, Davis, BM, Horvath, PB, Johns, CA, Mohs, RC.The study of cholinomimetics in Alzheimer’s disease and animal models. Iversen, SD.Psychopharmacology: Recent advances and future prospects. Oxford University Press (Oxford, New York, Tokyo) 1985.
60.Hollander, E, Mohs, RC, Davis, KL.Cholinergic approaches to the treatment of Alzheimer’s disease. British Medical Bulletin 1986; 42: 97100.
61.Arai, H, Kosaka, K, lizuka, T.Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochemistry 1984; 43: 388393.
62.Huygens, P, Baratti, CM, Gardella, JL, Filinger, E.Brain catecholamines modification. The effects on memory facilitation induced by oxotremorineinmice. Psychopharmacology 1980; 69:291294.
63.Mason, ST, Fibiger, HC.Possible behavioral function for noradrenaline-acetylcholine interaction in brain. Nature 1979; 277: 396397.
64.Waterhouse, BD, Moises, HC, Woodwark, DJ.Alpha-receptormediated facilitation of somatosensory cortical neuronal responses to excitatory synaptic inputs and iontophoretically applied acetylcholine. Neuropharmacology 1981; 20: 907920.
65.Vizi, ES.Modulation of cortical release of acetylcholine by noradrenaline released from nerves arising from the rat locus coeruleus. Neuroscience 1980; 5: 21392144.
66.Gash, DM, Collier, TJ, Sladek, JR Jr. Neural transplantation: A review of recent developments and potential application to the aged brain. Neurobiology of Aging 1985, 6: 131150.
67.Dunnett, SB, Low, WC, Iversen, SD, Stenevi, U, Bjorklund, A.Septal transplants restore maze learning in rats with fornix-fimbria lesions. Brain Research 1982; 251: 335348.
68.Kimble, DP, Breiller, R, Stickrod, G.Fetal brain implants improvemaze performance in hippocampal-lesioned rats. Brain Research 1986; 363: 358363.
69.Haroutunian, V, Kanof, PD, Davis, KL.Partial behavioral, histochemical and neurochemical restoration of fimbria/fornix lesion-induced deficits by septal transplants (in review).
70.Dunnett, SB, Tonilo, G, Fine, A, Ryan, CN, Bjorklund, A, Iversen, SD.Transplantation of embryonic ventral forebrain neurons to the neocortex of rats with lesions of nucleus basalis magnocel-lularis-Il. Sensorimotor and learning impairments. Neuroscience 1985; 16: 787797.
71.Fine, A, Dunnett, SB, Bjorklund, A, Iverson, SD.Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer’s disease. Proceedings of the National Academy of Science, USA 1985; 82: 52275229.
72.Appel, SH.A unifying hypothesis for the causes of amyotrophic lateral sclerosis, parkinsonism and Alzheimer’s disease. Annals of Neurology 1981; 10: 499505.
73.Hefti, F.Is Alzheimer’s disease caused by lack of nerve growth factor? Annals of Neurology 1983; 13: 109110.
74.Thoenen, H, Edgar, D.Neurotrophic factors. Science 1985; 229: 238242.
75.Shooter, EM, Yankner, BA, Landreth, GE, Sutter, A.Biosynthesis and mechanism of action of nerve growth factor. Recent Progress in Hormone Research 1981; 37: 417466.
76.Thoenen, H, Barde, Y-A.Physiology of nerve growth factor. Physiological Reviews 1980; 60: 12841335.
77.Bass, NH.Ganglioside sialic acid as a quantitative neurochemical index of the integrity of synaptic function in cognitive disorders of development and aging. In: Rapport, MM, Gorio, A, eds. Gangliosides in Neurological and Neuromuscular Function, Raven Press, New York 1981; 2942.
78.Hefti, F, Dravid, A, Hartikka, J.Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltrans-ferase activity in adult rats with partial septo-hippocampal lesions. Brain Research 1984; 293: 305311.
79.Mobley, WC, Rutkowski, JL, Tennekoon, GI, Buchanan, K, Johnston, MV.Choline acepy transferase activity in spriatum of neo-natal rats increased by nerve growth factor. Science 1985; 229: 284287.
80.Haroutunian, V, Kanof, P, Davis, KL.Partial reversal of lesioninduced deficits in cortical cholinergic markers by nerve growth factor. Brain Research (in press).
81.Seiler, M, Schwab, ME.Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Research 1984; 300: 3339.
82.Stein, DG, Will, BE.Nerve growth factor produces a temporary facilitation of recovery from entorhinal cortex lesions. Brain Research 1983,261: 127131.
83.Finger, S, Stein, DG.Brain damage and recovery: research and clinical perspectives. Academic Press, New York 1982; 227256.
84.Sabel, BA, Slavin, MD, Stein, DG.GMI, ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science 1984; 225: 340341.
85.Sabel, BA, Dunbar, GL, Stein, DG.Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. J Neuroscience Research 1984; 12: 429443.
86.Wojcik, M, Ulas, J, Oderfeld-Nowak, B.The stimulating effect of ganglioside injections on the recovery of choline acetyltransferase and acetylcholinesterase activities in the hippocampus of the rat after septal lesions. Neuroscience 1982; 7: 495499.
87.Oderfeld-Nowak, B, Skup, M, Ulas, J, Jezierska, M, Gradkowska, M, Zaremba, M.Effect of GMI ganglioside treatment on postlesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations. J Neuroscience Research 1984; 12: 409420.
88.Karpiak, SE.Ganglioside treatment improves recovery of alternation behavior after unilateral entorhinal cortex lesion. Experimental Neurology 1983; 81: 330339.
89.Oderfeld-Nowak, B, Wojcik, M, Ulas, J, Potempska, A.Effects of chronic ganglioside treatment on recovery processes in hippocampus after brain lesions in rats. In: Rapport, MM, Gorio, A, eds. Gangliosides in Neurological and Neuromuscular Function, Raven Press, New York 1981; 197209.
90.Toffano, G, Agnati, LF, Fuxe, K, Aldina, C, Consolazione, A, Valenti, G, Savoini, G.Effect of GMI ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesions. Acta Physiol Scand 1984; 122: 313321.
91.Agnati, LF, Fuxe, K, Calza, L, Benfenati, F, Cavicchioli, L, Toffano, G, Goldstein, M.Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol Scand 1983; 119: 347363.
92.Cuello, AC, Stephens, PH, Tagari, PC, Sofroniew, MV, Pearson RCA. Retrograde changes in the nucleus basalis of the rat, caused by cortical damage, are prevented by exogenous ganglioside GMI. Brain Research 1986; 376: 373377.
93.Li, YS, Mahadik, SP, Rapport, MM, Karpiak, SE.Acute effects of GMI ganglioside: Reduction in both behavioral asymmetry and loss of Na+, K+ -ATPase after nigrostriatal transection. Brain Research 1986; 377: 292297.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed